Eli Lilly (LLY): Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AAPL
6. HOOD
7. QCOM
8. ACN
9. AZN
10. ROIV

Go back to Eli Lilly (LLY): Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1123.91 -25.45 (2.21%)
Previous Close $1149.36    52 Week High $88.16 
Open $1133.00    52 Week Low $67.88 
Day High $1134.53    P/E 260.16 
Day Low $1113.55    EPS $4.32 
Volume 2,402,850